(Q61512804)
Statements
Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy? (English)
Vicki Thallas-Bonke
Josefa Pete
Maryann Arnstein
Melinda T Coughlan
David M Long
David C K Tong
Suzanne R Thorpe
Mark E Cooper
16 November 2006